CEL-SCI (NYSE:CVM) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of CEL-SCI (NYSE:CVM) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the stock.

CEL-SCI Price Performance

NYSE:CVM opened at $0.30 on Thursday. The firm has a market capitalization of $23.31 million, a price-to-earnings ratio of -0.63 and a beta of 0.67. CEL-SCI has a 52-week low of $0.29 and a 52-week high of $2.39. The stock has a fifty day moving average of $0.39 and a 200 day moving average of $0.70. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.09 and a current ratio of 1.07.

Institutional Investors Weigh In On CEL-SCI

Large investors have recently added to or reduced their stakes in the business. Plotkin Financial Advisors LLC bought a new stake in CEL-SCI during the third quarter valued at $98,000. Thoroughbred Financial Services LLC lifted its stake in CEL-SCI by 40.1% during the fourth quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock worth $76,000 after purchasing an additional 54,900 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in CEL-SCI by 9.6% during the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock worth $650,000 after purchasing an additional 53,879 shares during the last quarter. Institutional investors own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.